Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Myeloid Therapeutics
Bristol-Myers Squibb
The Netherlands Cancer Institute
Daiichi Sankyo
Molecular Templates, Inc.
Taris Biomedical LLC
Ikena Oncology
Tempest Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center